Glycomic Therapeutics Market Report 2026

The glycomic therapeutics market size has grown rapidly in recent years. It will grow from $189.51 billion in 2025 to $221.98 billion in 2026 at a compound annual growth rate (CAGR) of 17.1%. The growth in the historic period can be attributed to advances in glycobiology research, enzyme therapy development, rare disease drug approvals, academic research funding, biologics manufacturing growth.

The glycomic therapeutics market size is expected to see rapid growth in the next few years. It will grow to $424.67 billion in 2030 at a compound annual growth rate (CAGR) of 17.6%. The growth in the forecast period can be attributed to precision medicine adoption, glycan biomarker discovery, expansion of orphan drug pipelines, synthetic biology innovation, increased pharma research investment. Major trends in the forecast period include expansion of glycan-based drug development, growing focus on immune modulation therapies, increasing use of enzyme replacement therapies, rising research on rare and metabolic diseases, growth of synthetic glycan technologies.

The rising prevalence of diabetes is expected to drive the growth of the glycomic therapeutics market in the coming years. Diabetes is a chronic condition that affects the body’s ability to regulate blood glucose levels. Alterations in glycans have been observed in diabetic patients, contributing to insulin resistance and other metabolic issues. Specific glycan patterns serve as biomarkers for diagnosing diabetes, monitoring treatment responses, and predicting disease progression. For instance, in March 2025, GOV.UK, a UK-based government organization, reported that the prevalence of type 2 diabetes in adults aged 17 and over in England was 7% in March 2024, up from 6.8% in March 2023. Therefore, the rising prevalence of diabetes is fueling the growth of the glycomic therapeutics market.

The increasing prevalence of cancer is expected to propel the growth of the glycomic therapeutics market going forward. Cancer is characterized by the uncontrolled growth and spread of abnormal cells in the body. Glycomic therapeutics target and modify specific sugar molecules on cell surfaces to influence critical cellular interactions, signaling pathways, and immune responses, aiming to inhibit tumor growth and enhance the effectiveness of cancer therapies. For instance, in 2023, the American Cancer Society, a US-based nationwide health organization, reported that the estimated number of new liver cancer cases in females in the United States rose from 12,660 in 2022 to 13,230 in 2023. Therefore, the increasing prevalence of cancer is driving the growth of the glycomic therapeutics market.

Major companies in the glycomic therapeutics market are focusing on developing innovative solutions such as glyco-immune checkpoint inhibitors to counter tumor immune evasion and improve treatment efficacy. Glyco-immune checkpoint inhibitors are designed to block immunosuppressive sugar molecules on cancer cells, enabling the immune system to better recognize and attack tumors. For example, in June 2023, Palleon Pharmaceuticals Inc., a US-based biopharmaceutical company, announced that the first patient had been dosed in the combination therapy cohort of the Phase 1/2 GLIMMER-01 clinical trial. This trial is evaluating their lead glyco-immunology candidate E-602 both as a monotherapy and in combination with cemiplimab (Libtayo®) in patients with advanced cancers, assessing safety, pharmacodynamics, and antitumor activity. E-602 is a first-in-class glyco-immune checkpoint inhibitor designed to enzymatically degrade immunosuppressive sialoglycans on tumor and immune cells, aiming to restore antitumor immunity.

Major companies operating in the glycomic therapeutics market are F Hoffmann-La Roche Ltd., Sanofi SA, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Merck KGaA, Agilent Technologies Inc., AMS Bio, Shimadzu Corporation, Waters Corporation, Bruker Corporation, BioMarin Pharmaceutical Inc., Bio Techne Corp., Halozyme Therapeutics Inc., Takara Bio Inc., Vector Laboratories, New England Biolabs Inc., Protalix Biotherapeutics Inc., Genovis AB, Ludger Ltd, GlycoMar Limited.

North America was the largest region in the glycomic therapeutics in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glycomic therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the glycomic therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the glycomic therapeutics market by increasing costs of imported enzymes, reagents, bioprocessing equipment, and specialty raw materials. Pharmaceutical and biotechnology companies in North America and Europe are most affected due to reliance on imported inputs. These tariffs raise development costs by increasing expenses for research, scale-up, and manufacturing of glycan-based therapies. However, they support domestic biomanufacturing capabilities, strengthening regional infrastructure for advanced therapeutic development.

The glycomic therapeutics market research report is one of a series of new reports that provides glycomic therapeutics market statistics, including glycomic therapeutics industry global market size, regional shares, competitors with a glycomic therapeutics market share, detailed glycomic therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the glycomic therapeutics industry. This glycomic therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Glycomic therapeutics refers to the development of therapies based on glycomics, the study of the complete set of glycans in a cell or organism. The glycome is essential for understanding the complexity of biological systems and their relevance to health and disease. Glycans play key roles in various biological processes, including cell signaling, immune response, and disease progression.

The main classes of glycomic therapeutics are isolated and synthetic. Isolated glycomic therapy focuses on studying glycans individually, emphasizing the structural and functional characterization of specific glycan molecules. Synthetic glycomic therapy involves the use of synthetic glycans or glycan-based molecules for diagnosing and treating medical conditions. The various structures include glycoproteins targeting sialic acid, proteoglycans targeting glycosaminoglycans, glycosylphosphatidylinositol (GPI)-anchored proteins, heparin-based glycans targeting glycosphingolipids, and others. These therapeutics act through multiple mechanisms, such as inhibiting neuraminidase, inhibiting heparanase and selectins, blocking interactions between growth factors and heparan sulfate, erythropoietin and enzyme replacement therapy (ERT), tissue plasminogen activator, inhibiting glucosylceramide synthase, interleukins 1, 2, and 3, beta and gamma interferons, and more. They are indicated for a variety of conditions, including thrombosis and chemoprophylaxis, anemia, anti-adhesive and anti-inflammatory purposes, cataracts, Gaucher’s disease, MPS-1 and IV, cancer, Alzheimer’s disease, influenza types A and B, and others.

The glycomic therapeutics market consists of sales of investigational glycomic therapeutics and therapeutic glycomic that target glycans or glycan-related pathways for the diagnosis and treatment of diseases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.